Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;29(Suppl):S302-S318.
doi: 10.3350/cmh.2022.0329. Epub 2022 Nov 15.

Non-alcoholic fatty liver disease: the pathologist's perspective

Affiliations
Review

Non-alcoholic fatty liver disease: the pathologist's perspective

Wei-Qiang Leow et al. Clin Mol Hepatol. 2023 Feb.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases characterized by fatty accumulation in hepatocytes, ranging from steatosis, non-alcoholic steatohepatitis, to cirrhosis. While histopathological evaluation of liver biopsies plays a central role in the diagnosis of NAFLD, limitations such as the problem of interobserver variability still exist and active research is underway to improve the diagnostic utility of liver biopsies. In this article, we provide a comprehensive overview of the histopathological features of NAFLD, the current grading and staging systems, and discuss the present and future roles of liver biopsies in the diagnosis and prognostication of NAFLD.

Keywords: Biopsy; Diagnosis; Histology; Non-alcoholic fatty liver disease; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts to disclose.

Figures

Figure 1.
Figure 1.
Steatosis. A combination of large and small droplet macrovesicular steatosis is seen in this example of non-alcoholic steatohepatitis. In large droplet macrovesicular steatosis, the fat droplet occupies more than half of the hepatocyte cytoplasm and pushes the nucleus to the edge of the cell (black arrows). Smaller droplets are also seen. A small patch of microvesicular steatosis is noted on the right (black star), characterized by innumerable tiny fat droplets in the hepatocyte cytoplasm. A few ballooned hepatocytes are also noted (white arrows) (H&E, original magnification ×200).
Figure 2.
Figure 2.
The many faces of ballooned hepatocytes (A–C: H&E, original magnification x400). (A) A cluster of classical ballooned cells. (B) Occasionally the cytoplasmic keratins aggregate to form tighter and more eosinophilic clumps, also known as Mallory-Denk bodies (black arrowhead). (C) A lonely non-classical ballooned cell (black arrow) which is similar in size to the adjacent non-ballooned hepatocytes.
Figure 3.
Figure 3.
Lobular necroinflammation. Foci of lobular spotty necrosis are seen in this example of non-alcoholic steatohepatitis (yellow circles). The inflammatory cell infiltrations are mainly composed of mononuclear cells (H&E, original magnification ×200).
Figure 4.
Figure 4.
Stages of fibrosis and the utility of histochemical stains in accentuating the histological appearance. (A1, A2) The classical ‘chickenwire’ appearance of pericellular fibrosis is accentuated with a Sirius Red histochemical stain, which reveals the collagen fibers in red. (B1, B2) Stage 2 fibrosis is the co-presence of pericellular fibrosis and also portal fibrosis. Masson Trichrome stain shows the blue pericellular collagen fibers on the left and the portal fibrosis on the right. (C1, C2) The fibrosis extends across the hepatic lobules and forms bridging fibrosis. (D1, D2) The presence of hepatocytic nodules heralds cirrhosis, with Masson Trichrome stain confirming the broad fibrous bands. Original magnification ×200 (A1, A2), ×40 (B1–D2); H&E (A1, B1, C1, D1), Sirius Red (A2), Masson Trichrome (B2, C2, D2).
Figure 5.
Figure 5.
An example of a case of non-alcoholic fatty liver disease -cirrhosis seen by second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) (SHG/TPEF microscopy, scanning power).

Similar articles

Cited by

References

    1. European Association for the Study of the Liver (EASL) EuropeanAssociation for the Study of Diabetes (EASD) EuropeanAssociation for the Study of Obesity (EASO) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402. - PubMed
    1. Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27:363–401. - PMC - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. - PubMed
    1. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16:5286–5296. - PMC - PubMed
    1. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175–1183. - PubMed